IBRX261023C00010500
IBRX Oct 23 2026 10.50 Call
optionOPRA
EODOct 16, 2026
0.15USD-57.143%(-0.20)227Vol1,477OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
10.5
Expiration
Oct 23, 2026
DTE
3d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.15 | -57.14% | 227 | 1,477 |
| Oct 30, 2026 | 10d | $0.22 | -60.00% | 64 | 468 |
| Nov 6, 2026 | 17d | $0.65 | -14.47% | 4 | 44 |
| Nov 13, 2026 | 24d | $0.61 | -33.70% | 13 | 56 |
| Nov 27, 2026 | 38d | $0.85 | -39.29% | 6 | 103 |
IBRX Nearby Strikes · Oct 23, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 7.5 C | $2.47 | -14.83% | 13 | 24 | ITM |
| 8 C | $2.17 | +3.33% | 11 | 23 | ITM |
| 8.5 C | $1.82 | -4.71% | 11 | 95 | OTM |
| 9 C | $0.50 | -60.00% | 168 | 243 | OTM |
| 9.5 C | $0.28 | -65.00% | 263 | 438 | OTM |
| 10 C | $0.18 | -55.00% | 1,199 | 1,985 | OTM |
| 10.5 C | $0.15 | -57.14% | 227 | 1,477 | OTM |
| 11 C | $0.05 | -80.00% | 54 | 1,377 | OTM |
| 11.5 C | $0.05 | -82.14% | 7 | 143 | OTM |
| 12 C | $0.05 | -50.00% | 125 | 190 | OTM |
| 12.5 C | $0.09 | -55.00% | 1 | 16 | OTM |
| 13 C | $0.10 | -73.68% | 20 | 41 | OTM |
| 13.5 C | — | — | 0 | 0 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.